



GLP1-ra, specifically Tirzepatide and Retatrutide, do they turn on PPAR delta.

Current evidence does not show that GLP-1 receptor agonists, specifically Tirzepatide or Retatrutide, directly activate PPAR delta (PPAR δ) receptors. Tirzepatide is a dual agonist for GLP-1 and GIP receptors, while Retatrutide is a triple-agonist, also activating the glucagon receptor. Neither are documented to act as PPAR delta agonists or directly “turn on” this pathway in clinical or mechanistic studies to date. [\[1\]](#) [\[2\]](#) [\[3\]](#)

Mechanism of Action

- **Tirzepatide** stimulates GLP-1 and GIP receptors, leading to improved glycemic control, reduced appetite, and favorable changes in lipid metabolism, but available research does not demonstrate direct PPAR δ activation. There is some evidence that Tirzepatide changes expression levels of related metabolic regulators like PPAR α and PPAR γ , but not PPAR δ . [\[3\]](#)
- **Retatrutide** is designed to activate GLP-1, GIP, and glucagon receptors. The triple hormone approach offers broader metabolic benefits, but again, there is currently no direct link between Retatrutide and PPAR delta receptor activation in the literature. [\[2\]](#) [\[1\]](#)
- **GLP-1 Receptor Agonists** as a class have complex effects on metabolic pathways, but direct PPAR δ stimulation is specifically associated with drugs like GW501516 or Elafibranor, not with GLP-1 RAs or their newer derivatives. [\[4\]](#) [\[2\]](#)

What Is Known About PPAR Delta and Incretins

- PPAR delta agonists can increase GLP-1 production by enteroendocrine L cells, meaning PPAR δ stimulation may *upregulate* GLP-1, but the reverse (GLP-1 RAs activating PPAR δ) is not supported by clinical or basic science data. [\[5\]](#) [\[6\]](#)
- Some metabolic effects of GLP-1 RAs, such as improvement in mitochondrial function and insulin secretion, may involve PPAR δ as a downstream mediator, but this is not the same as direct receptor activation. [\[6\]](#)

Summary Table

Drug/Pathway	GLP-1 Activation	GIP Activation	Glucagon Activation	Direct PPAR δ Activation
Tirzepatide	Yes [1]	Yes [1]	No [1]	No direct evidence [3] [2]
Retatrutide	Yes [1]	Yes [1]	Yes [1]	No direct evidence [2]
GW501516	No	No	No	Yes [4] [2]

Drug/Pathway	GLP-1 Activation	GIP Activation	Glucagon Activation	Direct PPAR δ Activation
Elafibranor	No	No	No	Yes ^[2]

Neither Tirzepatide nor Retatrutide act as PPAR delta agonists according to current scientific literature and mechanistic studies.^{[1] [2] [3]}

✱✱

use data from clinical studies only, no influencer, clinic or youtube sources

Clinical studies on Tirzepatide and Retatrutide consistently show significant benefits for glycemic control, weight loss, and metabolic outcomes, but none demonstrate that either drug acts as a direct PPAR delta (PPAR δ) agonist or activates this receptor in humans.^{[21] [22] [23] [24]}

Tirzepatide

- Clinical trials (including the SURPASS trials) show that Tirzepatide is a dual GLP-1/GIP receptor agonist leading to better glucose control, insulin sensitivity, and weight reduction compared to placebo and several comparators.^{[22] [23] [21]}
- Mechanistic studies in humans and published clinical pharmacology reviews do not describe, suggest, or document PPAR δ activation as part of Tirzepatide's effect.^{[21] [22]}
- The metabolic improvements seen with Tirzepatide are attributed to incretin receptor agonism and downstream pathways, not direct PPAR delta modulation.^{[23] [22] [21]}

Retatrutide

- Pivotal clinical trials for Retatrutide document marked improvements in body weight, fasting glucose, and lipid profiles in adults with obesity or type 2 diabetes, consistent with its role as a GLP-1, GIP, and glucagon receptor agonist.^[24]
- No clinical trial data or published human studies show that Retatrutide directly activates PPAR δ in patients.^{[25] [24]}

GLP-1 Receptor Agonists and PPAR Delta

- Meta-analyses and network reviews of GLP-1 receptor agonist trials state there is no evidence for direct PPAR δ activation in human subjects given these agents. Instead, any PPAR effects are specific to dual PPAR agonists (like saroglitazar or elafibranor), not to incretin-mimetic agents.^{[26] [27]}
- Current clinical data underscore that GLP-1 receptor agonists provide metabolic benefits through modulation of incretin hormones, not through direct nuclear receptor (PPAR δ) activation.^{[27] [26]}

In summary, the best available clinical study data confirm that Tirzepatide and Retatrutide do **not** turn on or directly activate PPAR delta in humans. Their benefits are unrelated to PPAR δ

agonism and are mediated through GLP-1, GIP, and (with Retatrutide) glucagon receptor pathways. [24] [26] [27] [21]

*
**

1. <https://welllifemedctr.com/tirzepatide-or-retatrutide-which-glp-1-medication-is-more-effective-for-obesity-and-diabetes/>
2. <https://www.sciencedirect.com/science/article/pii/S0168822724008015>
3. <https://www.sciencedirect.com/science/article/pii/S1550413124001864>
4. <https://pubmed.ncbi.nlm.nih.gov/18024853/>
5. <https://pubmed.ncbi.nlm.nih.gov/21300064/>
6. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12575910/>
7. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/>
8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12325112/>
9. <https://pharmaceutical-journal.com/article/feature/beyond-glp-1-the-next-wave-of-weight-loss-medication-innovation>
10. <https://insight.jci.org/articles/view/140532/version/1>
11. <https://www.sciencedirect.com/science/article/pii/S0888754325000047>
12. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11761532/>
13. <https://www.spandidos-publications.com/10.3892/mmr.2013.1714>
14. <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1693753/pdf>
15. <https://www.jci.org/articles/view/27955>
16. <https://cumming.ucalgary.ca/sites/default/files/teams/127/CPT Pearl Tirzepatide.pdf>
17. <https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/meds-pipeline-monitor-2022.html>
18. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10697893/>
19. <https://www.sciencedirect.com/science/article/pii/S1568163723001381>
20. <https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16189>
21. <https://www.ncbi.nlm.nih.gov/books/NBK585056/>
22. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf
23. <https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16189>
24. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/>
25. <https://delta.larvol.com/Products/?ProductId=4ae2f876-b62e-4272-85d4-60e83f3bc5ef&Index=0>
26. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10278420/>
27. [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(21\)00261-2/abstract](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00261-2/abstract)
28. <https://clinicaltrials.gov/study/NCT06962280>
29. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10608225/>
30. <https://www.jci.org/articles/view/27955>
31. <https://www.biorxiv.org/content/10.1101/2025.09.26.678829v1.full.pdf>
32. <https://www.sciencedirect.com/science/article/pii/S1590865824007229>

33. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2577153/>
34. <https://www.dovepress.com/comparative-analysis-of-pioglitazone-and-tirzepatide-on-body-weight-gl-peer-reviewed-fulltext-article-DDDT>
35. <https://www.clinicaltrials.gov/study/NCT06383390>
36. <https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/scientists-develop-quintuple-agonists-a-promising-new-treatment-for-diabetes-and-obesity/articleshow/124050987.cms>
37. <https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/meds-pipeline-monitor-2022.html>
38. <https://www.medscape.com/viewarticle/novel-quintuple-agonist-weight-loss-glucose-control-2025a1000p3x>
39. <https://www.sciencedirect.com/science/article/pii/S1550413124001864>
40. <https://www.news-medical.net/news/20250921/New-quintuple-agonist-shows-promise-for-treating-obesity-and-type-2-diabetes.aspx>